Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

B. Riley Securities Initiates Coverage On Theravance Biopharma with Buy Rating, Announces Price Target of $28

Author: Benzinga Newsdesk | September 12, 2025 04:33am
B. Riley Securities analyst Mayank Mamtani initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Buy rating and announces Price Target of $28.

Posted In: TBPH


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist